niacin

(redirected from Niaspan)
Also found in: Dictionary, Thesaurus, Medical.
Related to Niaspan: niacin

niacin:

see coenzymecoenzyme
, any one of a group of relatively small organic molecules required for the catalytic function of certain enzymes. A coenzyme may either be attached by covalent bonds to a particular enzyme or exist freely in solution, but in either case it participates intimately in
..... Click the link for more information.
; vitaminvitamin,
group of organic substances that are required in the diet of humans and animals for normal growth, maintenance of life, and normal reproduction. Vitamins act as catalysts; very often either the vitamins themselves are coenzymes, or they form integral parts of coenzymes.
..... Click the link for more information.
.

niacin

[′nī·ə·sən]
(biochemistry)
References in periodicals archive ?
And the report says apart from causing increased rate of infection, there is also higher rate of serious bleeding associated with Niaspan.
According to the company, NIASPAN is marketed by AbbVie and is used with diet to reduce elevated TC, LDL-C, Apo B and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
No, not if you are able to maintain very low levels of LDL cholesterol, said the authors of the Niaspan study--a position reinforced in an editorial accompanying the article in the New England Journal of Medicine.
Restrepo Valencia and Cruz (2008) used Niaspan for eight months with three individuals on hemodialysis and six on peritoneal dialysis.
Products Released by 240 min Dissolution Rate (a) (mg/hr) Niaspan 41.
Niaspan is much better tolerated, but it's quite expensive.
Three forms of niacin exist: immediate-release (IR), sustained-release/long-acting (SR/LA), and extended-release (ER), which is currently available only as Niaspan.
The three-year agreement on the drugs, Niaspan and Advicor, will take effect in January, enabling Takeda Pharmaceuticals North America Inc.
As an example of the type of work the group does, Tuten cited a 2006 case on behalf of Kos Pharmaceuticals, the maker of the cholesterol drug Niaspan.
of a clinical trial of Niaspan (which raises HDL) and simvastatin (which
The NIH has ceased a study with Abbott Laboratories' cholesterol fighter Niaspan 18 months early after results showed the drug wasn't successful in preventing heart attacks and may even have increased stroke risk.
He was also part of Kos Pharmaceuticals, where he played an integral role in the launch and successful commercialisation of Niaspan.